Metformin Normalizes Nonoxidative Glucose Metabolism in Insulin-Resistant Normoglycemic First-Degree Relatives of Patients With NIDDM
The DOI matches its Crossref record.
Abstract
Many first-degree relatives of patients with non-insulin-dependent diabetes mellitus (NIDDM) are characterized by insulin resistance. Because metformin improves peripheral insulin sensitivity, we examined the acute effect of metformin and placebo on glucose and lipid metabolism in nine insulin-resistant first-degree relatives of NIDDM patients with the euglycemic insulin-clamp technique combined with indirect calorimetry and infusion of [3-3H]glucose. Either placebo or 500 mg metformin was taken in random order twice the day before and once 1 h before the clamp. Nine healthy individuals without family history of diabetes served as control subjects. Basal plasma glucose was normal and did not differ between the metformin and the placebo study (4.8 ± 0.2 vs. 5.0 ± 0.2 mM) and neither did basal hepatic glucose production (10.59 ± 0.54 vs. 10.21 ± 0.80 μmol · kg−1 · min−1). Insulin-stimulated glucose disposal was significantly increased by 25% after metformin compared with placebo (26.67 ± 2.87 vs. 21.31 ± 1.73 μmol kg−1 min−1 P < 0.05). The enhancement in glucose utilization was primarily due to normalization of nonoxidative glucose disposal (from 8.02 ± 1.35 to 15.07 ± 2.69 μmol kg−1 min−1 P < 0.01, vs. 15.65 ± 2.72 μmol kg−1 min−1 in control subjects). In contrast, glucose oxidation during the clamp was slightly lower after metformin compared with both placebo (11.59 ± 0.83 vs. 13.30 ± 1.00 μmol kg−1 min−1 P = 0.06) and healthy control subjects (15.68 ± 1.38 μmol kg−1 min−1 P < 0.05). We conclude that acutely administered metformin improves peripheral insulin sensitivity in insulin-resistant normoglycemic individuals primarily by stimulating the nonoxidative pathway of glucose metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ross, R., Dagnone, D., Jones, P. J. H., Smith, H., Paddags, A., Hudson, R., & Janssen, I. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-2-200007180-00008 · Cited by 1,435
“From a therapeutic perspective, it is noted that insulin sensitivity improved by approximately 60% in the weight loss groups, an increase greater than the 25% improvement in insulin sensitivity observed in response to metformin (46) and troglitazone (47).”
BackgroundEfficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
“Other§ 21 (14) 15 (10) 24 (11) 27 (13) 16 (8)1”
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
“Metformin also enhances muscle insulin sensitivity (90, 92–94, 96) through direct (97, 98) and indirect effects (99).”
BackgroundVelazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865
Cellular and Molecular Mechanisms of Metformin Action
LaMoia, T. E., & Shulman, G. I. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa023 · Cited by 791
Metadata
- Authors
- Widén, E. I. M., Eriksson, J. G., & Groop, L. C.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1992-03-01
- Volume
- 41
- Issue
- 3
- Pages
- 354-358
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2032539515
- Cited by
- 111
- References
- 0
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin Normalizes Nonoxidative Glucose Metabolism in Insulin-Resistant Normoglycemic First-Degree Relatives of Patients With NIDDM. https://app.cochat.ai/papers/10.2337/diab.41.3.354
- The paper
- Widén, E. I. M., Eriksson, J. G., & Groop, L. C. (1992). Metformin Normalizes Nonoxidative Glucose Metabolism in Insulin-Resistant Normoglycemic First-Degree Relatives of Patients With NIDDM. Diabetes. https://doi.org/10.2337/diab.41.3.354
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.